Arcus Biosciences saw the highest growth of 1.99% in patent filings in June and 1.66% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 1.49%. GlobalData’s DataBook provides a comprehensive analysis of Arcus Biosciences‘s patent filings and grants. Buy the databook here.
Arcus Biosciences has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 30% filings and 22% grants. The World Intellectual Property Organization(WIPO), United States(US), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Arcus Biosciences is filings its patents. Among the top granted patent authorities, Arcus Biosciences has 22% of its grants in United States(US), 22% in Australia(AU) and 22% in Spain(ES).
Roche and Johnson & Johnson could be the strongest competitors for Arcus Biosciences
Patents related to cell & gene therapy and rare diseases lead Arcus Biosciences's portfolio
Arcus Biosciences has the highest number of patents in cell & gene therapy followed by, rare diseases. For cell & gene therapy, nearly 60% of patents were filed and no patents were granted in Q2 2024.
Lung cancer related patents lead Arcus Biosciences portfolio followed by lymphoma, and breast cancer
Arcus Biosciences has highest number of patents in lung cancer followed by lymphoma, breast cancer, uterine cancer, and advanced malignancy. For lung cancer, nearly 6% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of Arcus Biosciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.